Parallax Volatility Advisers’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.12M Sell
15,900
-47,800
-75% -$6.69M 0.01% 772
2025
Q4
$7.82M Sell
63,700
-1,300
-2% -$158K 0.02% 532
2025
Q3
$7.21M Sell
65,000
-108,800
-63% -$12.4M 0.01% 577
2025
Q2
$19.3M Buy
173,800
+117,700
+210% +$12.5M 0.04% 283
2025
Q1
$6.29M Buy
56,100
+54,200
+2,853% +$5.59M 0.02% 561
2024
Q4
$176K Sell
1,900
-45,800
-96% -$4.12M ﹤0.01% 1682
2024
Q3
$4M Sell
47,700
-44,600
-48% -$3.4M 0.01% 888
2024
Q2
$6.33M Sell
92,300
-124,800
-57% -$8.33M 0.01% 633
2024
Q1
$15.9M Sell
217,100
-364,500
-63% -$28M 0.04% 372
2023
Q4
$47.1M Buy
581,600
+314,300
+118% +$24.5M 0.1% 190
2023
Q3
$20M Buy
267,300
+173,300
+184% +$13.3M 0.04% 335
2023
Q2
$7.24M Buy
94,000
+48,800
+108% +$3.89M 0.02% 636
2023
Q1
$3.75M Sell
45,200
-68,700
-60% -$5.69M 0.01% 983
2022
Q4
$9.78M Sell
113,900
-151,400
-57% -$12M 0.02% 780
2022
Q3
$16.4M Sell
265,300
-135,100
-34% -$8.52M 0.03% 580
2022
Q2
$24.7M Buy
400,400
+74,300
+23% +$4.6M 0.02% 425
2022
Q1
$19.4M Sell
326,100
-124,500
-28% -$7.96M 0.01% 519
2021
Q4
$32.7M Buy
450,600
+78,800
+21% +$5.43M 0.04% 308
2021
Q3
$26M Buy
+371,800
New +$26.1M 0.03% 389
2021
Q1
Sell
-232,700
Closed -$13.6M 1414
2020
Q4
$13.6M Sell
232,700
-22,600
-9% -$1.36M 0.01% 638
2020
Q3
$16.1M Sell
255,300
-722,100
-74% -$50.1M 0.01% 799
2020
Q2
$75.2M Buy
977,400
+284,800
+41% +$21.8M 0.09% 175
2020
Q1
$51.8M Buy
692,600
+307,300
+80% +$21.2M 0.07% 200
2019
Q4
$25M Buy
385,300
+46,200
+14% +$3.01M 0.03% 365
2019
Q3
$21.5M Sell
339,100
-269,200
-44% -$17.6M 0.02% 374
2019
Q2
$41.1M Buy
608,300
+539,300
+782% +$35.5M 0.04% 210
2019
Q1
$4.49M Sell
69,000
-525,400
-88% -$34.9M 0.01% 718
2018
Q4
$37.2M Buy
594,400
+368,500
+163% +$25.8M 0.05% 230
2018
Q3
$17.4M Sell
225,900
-34,400
-13% -$2.6M 0.02% 331
2018
Q2
$18.4M Buy
260,300
+180,300
+225% +$12.7M 0.03% 291
2018
Q1
$6.03M Sell
80,000
-51,000
-39% -$4.05M 0.01% 469
2017
Q4
$9.38M Sell
131,000
-175,000
-57% -$13.3M 0.01% 432
2017
Q3
$24.8M Buy
306,000
+51,000
+20% +$3.9M 0.04% 221
2017
Q2
$18M Buy
+255,000
New +$17M 0.04% 273
2017
Q1
Sell
-126,700
Closed -$9.07M 3946
2016
Q4
$9.07M Sell
126,700
-108,900
-46% -$8.09M 0.02% 470
2016
Q3
$18.6M Buy
235,600
+72,900
+45% +$5.92M 0.03% 292
2016
Q2
$13.6M Buy
162,700
+53,800
+49% +$4.77M 0.03% 363
2016
Q1
$10M Sell
108,900
-109,100
-50% -$9.84M 0.02% 369
2015
Q4
$22.1M Sell
218,000
-123,700
-36% -$12.9M 0.04% 270
2015
Q3
$33.6M Buy
341,700
+288,800
+546% +$32.1M 0.07% 178
2015
Q2
$6.19M Sell
52,900
-557,800
-91% -$61M 0.01% 649
2015
Q1
$59.9M Buy
610,700
+428,800
+236% +$43.5M 0.14% 111
2014
Q4
$17.1M Buy
+181,900
New +$18.8M 0.05% 325
2014
Q3
Sell
-337,900
Closed -$28M 4252
2014
Q2
$28M Buy
337,900
+337,600
+112,533% +$26.3M 0.12% 137
2014
Q1
$21K Sell
300
-151,300
-100% -$11.9M ﹤0.01% 2774
2013
Q4
$11.4M Sell
151,600
-12,500
-8% -$870K 0.06% 266
2013
Q3
$10.3M Sell
164,100
-17,600
-10% -$1.05M 0.05% 252
2013
Q2
$9.32M Buy
+181,700
New +$9.47M 0.04% 282

Other funds holding GILD

Parallax Volatility Advisers's GILD Position: Q1 2026 in Review

Parallax Volatility Advisers increased its Gilead Sciences (GILD) stake by 3,738% in Q1 2026, buying an estimated $1.84M and bringing the position to 13,470 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #817.

Parallax Volatility Advisers first reported a position in GILD in Q3 2013 and has held it in 38 quarters since. The position peaked at $36.8M in Q4 2014. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Parallax Volatility Advisers held 13,470 shares of Gilead Sciences worth $1.8M as of Q1 2026.
  • Parallax Volatility Advisers bought 13,119 Gilead Sciences shares in Q1 2026, an estimated $1.84M.
  • Gilead Sciences made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q1 2026, its #817 holding.
  • Parallax Volatility Advisers first reported a position in Gilead Sciences in Q3 2013 and has held it in 38 quarters since.
  • Parallax Volatility Advisers's Gilead Sciences position peaked at $36.8M in Q4 2014.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.